I like the thought process speaking about end stage renal disease and not just DDD. This is the real possible cavet for CLDX and that would mean billions for CLDX. The key is to show progress in DDD then if we show slowing kidney function decline imagine what we could do for other patients with type 2 diabetes, patients with slowly failing kidney functions and progressing to end stage renal disease. Type 2 diabetes will die from either kidney function, heart attack or stroke or copd or chf, that is the market we would be entering after the DDD indication. But just one step at a time.